Immuron (IMRN) Total Current Liabilities (2016 - 2025)
Immuron's quarterly Total Current Liabilities came in at $19662.1 in Q3 2025, down 27.15% year-on-year from $26989.8 in Q3 2024, and down 98.44% quarter-over-quarter from $1.3 million in Q2 2025.
Immuron has reported Total Current Liabilities for 10 years, with the latest figure at $19662.1 in Q3 2025.
- For the quarter ending Q3 2025, Total Current Liabilities fell 27.15% year-over-year to $19662.1; the trailing twelve-month figure through Sep 2025 stood at $19662.1 (down 27.15% YoY), and the FY2025 full-year result was $19662.1, down 27.15% from the prior year.
- Total Current Liabilities for Q3 2025 stood at $19662.1, down from $1.3 million in the prior quarter.
- The five-year high for Total Current Liabilities was $1.8 million in Q2 2024, with the low at $11218.5 in Q2 2021.
- Average Total Current Liabilities over 5 years is $718982.2, with a median of $902379.4 recorded in 2022.
- Year-over-year, Total Current Liabilities soared 16564.71% in 2021 and tumbled 98.53% in 2023.
- Tracing IMRN's Total Current Liabilities over 5 years: stood at $817270.7 in 2021, then climbed by 20.83% to $987488.0 in 2022, then plunged by 98.53% to $14477.7 in 2023, then soared by 7708.68% to $1.1 million in 2024, then plunged by 98.26% to $19662.1 in 2025.
- The last three Total Current Liabilities figures came in at $19662.1 (Q3 2025), $1.3 million (Q2 2025), and $1.1 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | 19,662.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 19,662.09 |
| Jun 30, 2025 | 1.26 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 9, 2024 | 26,989.79 |
| Jun 30, 2024 | 1.78 Mn |
| Dec 31, 2023 | 14,477.66 |
| Sep 28, 2023 | 1.45 Mn |
| Aug 30, 2023 | 22,191.39 |
| Jun 30, 2023 | 1.48 Mn |
| Dec 31, 2022 | 987,488.00 |
| Aug 31, 2022 | 1.05 Mn |
| Jun 30, 2022 | 15,029.76 |
| Dec 31, 2021 | 817,270.73 |
| Jun 30, 2021 | 11,218.53 |
| Dec 31, 2020 | 4,904.20 |
| Sep 1, 2020 | 516,411.00 |
| Jun 30, 2020 | 338,466.42 |
| Dec 31, 2019 | 5,164.11 |
| Jun 30, 2019 | 837,436.32 |
| Dec 31, 2018 | 803,338.00 |
| Sep 27, 2018 | 587,944.04 |
| Aug 30, 2018 | 803,338.00 |
| Jun 30, 2018 | 608,156.52 |
| Dec 31, 2017 | 1.33 Mn |
| Sep 28, 2017 | 1.35 Mn |
| Aug 31, 2017 | 1.71 Mn |
| Jun 30, 2017 | 1.29 Mn |
| Dec 31, 2016 | 2.93 Mn |